Lung Cancer Screening Prevalence and Changes in 2024 - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Trends and Prevalence of Lung Cancer Screening in 2024

  • By

  • Todd Burus

  • Caree R. McAfee

  • Jennifer Redmond Knight

  • Timothy W. Mullett

  • Pamela C. Hull

  • June 1, 2026

Share

Clinical Scorecard: Trends and Prevalence of Lung Cancer Screening in 2024

At a Glance

CategoryDetail
Condition
Key MechanismsAnnual screening with low-dose computed tomography for high-risk individuals as per USPSTF guidelines.
Target PopulationAdults aged 50 to 80 years who are current smokers or have quit within 15 years, with a smoking history of 20 or more pack-years.
Care Setting

Key Highlights

  • 24.49% of eligible respondents were up-to-date on screenings in 2024.
  • UTD prevalence increased by 6.00 percentage points since 2022.
  • Significant increases in UTD prevalence among individuals with military-related insurance.
  • State-level UTD prevalence ranged from 13.43% in South Dakota to 38.36% in Massachusetts.

Guideline-Based Recommendations

Diagnosis

  • Annual lung cancer screening for eligible individuals as per USPSTF guidelines.

Management

  • Utilize low-dose computed tomography for screening.

Monitoring & Follow-up

  • Track screening uptake and prevalence across demographics and regions.

Risks

  • Potential biases in self-reported data and exclusion of adults aged 80 years.

Patient & Prescribing Data

Adults aged 50 to 80 years with specific smoking histories.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Lung Cancer Screening Prevalence and Changes in 2024

    • by Todd Burus, Caree R. McAfee, Jennifer Redmond Knight, Timothy W. Mullett, Pamela C. Hull

    • June 1, 2026

    Related Content

    What the Biggest ASCO Cancer Research Updates Could Mean for Patients

    Each year, the American Society of Clinical Oncology Annual Meeting brings together cancer specialists from around the world to share the research most likely to shape the next chapter of cancer care. This year’s major updates point to several important themes: more precise treatment, smarter use of surgery and chemotherapy, new approaches for difficult-to-treat cancers and a growing recognition that supportive care, including exercise, can be part of cancer treatment planning.

    • by

    • June 8, 2026

    • 10 min
    ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

    Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

    • July 1, 2026

    • 1 min
    Generalizability and Fairness in Deploying AI for Lung Cancer Biomarker Prediction